Review anchor
HeLa
CELL-LINE · Homo sapiens
As of 2026-09-14
Evidence Snapshot
HeLa
CHEMBL399
CELL-LINE
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats HeLa as ChEMBL target CHEMBL399. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL399
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why HeLa matters
HeLa is reviewed as HeLa; the current evidence base includes 122 approved drugs, 43208 compounds, and 12984 assays, with lead potency reaching pChEMBL 11.0.
Protein context
HeLa
HeLa
Review this target as HeLa.
Protein source · UniProt accession via ChEMBL component mappingDisease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 122 approved drugs, 43208 compounds, and 12984 assays for this target. The dominant activity type is IC50. CHEMBL1836551 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL1836551 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
122 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why HeLa matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
43208
Total Compounds
12984
Total Assays
122
Approved Drugs
IC50: 32597.0, EC50: 2077.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1836551
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL419165
|
11.0 | IC50 | — |
|
|
No preferred name
CHEMBL1836541
|
10.9 | IC50 | — |
|
|
No preferred name
CHEMBL316714
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL2377272
|
10.8 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ARTESUNATE
CHEMBL361497
|
2020 |
|
|
SELINEXOR
CHEMBL3545185
|
2019 |
|
|
ABEMACICLIB
CHEMBL3301610
|
2017 |
|
|
OSIMERTINIB
CHEMBL3353410
|
2015 |
|
|
BELINOSTAT
CHEMBL408513
|
2014 |
|
|
CERITINIB
CHEMBL2403108
|
2014 |
|
|
IDELALISIB
CHEMBL2216870
|
2014 |
|
|
TOFACITINIB
CHEMBL221959
|
2012 |
|
|
CABOZANTINIB
CHEMBL2105717
|
2012 |
|
|
OMACETAXINE MEPESUCCINATE
CHEMBL46286
|
2009 |
|
|
LAPATINIB
CHEMBL554
|
2007 |
|
|
VORINOSTAT
CHEMBL98
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
|
|
ERLOTINIB
CHEMBL553
|
2004 |
|
|
SIROLIMUS
CHEMBL413
|
1999 |
|
|
EFAVIRENZ
CHEMBL223228
|
1998 |
|
|
ANAGRELIDE
CHEMBL760
|
1997 |
|
|
DELAVIRDINE
CHEMBL593
|
1997 |
|
|
IRINOTECAN
CHEMBL481
|
1996 |
|
|
TOPOTECAN
CHEMBL84
|
1996 |
|
|
NEVIRAPINE
CHEMBL57
|
1996 |
|
|
GEMCITABINE
CHEMBL888
|
1996 |
|
|
TOPOTECAN HYDROCHLORIDE
CHEMBL1607
|
1996 |
|
|
DOCETAXEL ANHYDROUS
CHEMBL92
|
1995 |
|
|
DOCETAXEL
CHEMBL3545252
|
1995 |
|
|
VINORELBINE
CHEMBL553025
|
1994 |
|
|
VINORELBINE TARTRATE
CHEMBL538943
|
1994 |
|
|
PACLITAXEL
CHEMBL428647
|
1992 |
|
|
PODOFILOX
CHEMBL61
|
1990 |
|
|
MITOXANTRONE
CHEMBL58
|
1987 |
|
|
ZIDOVUDINE
CHEMBL129
|
1987 |
|
|
AMSACRINE
CHEMBL43
|
1987 |
|
|
ETOPOSIDE
CHEMBL44657
|
1983 |
|
|
ACYCLOVIR
CHEMBL184
|
1982 |
|
|
GENTIAN VIOLET
CHEMBL64894
|
1982 |
|
|
MITOMYCIN
CHEMBL105
|
1981 |
|
|
DAUNORUBICIN
CHEMBL178
|
1979 |
|
|
DAUNORUBICIN HYDROCHLORIDE
CHEMBL1563
|
1979 |
|
|
ESTRADIOL
CHEMBL135
|
1975 |
|
|
DOXORUBICIN
CHEMBL53463
|
1974 |
|
|
DOXORUBICIN HYDROCHLORIDE
CHEMBL359744
|
1974 |
|
|
FLOXURIDINE
CHEMBL917
|
1970 |
|
|
CYTARABINE
CHEMBL803
|
1969 |
|
|
VINBLASTINE
CHEMBL159
|
1965 |
|
|
DACTINOMYCIN
CHEMBL1554
|
1964 |
|
|
VINCRISTINE
CHEMBL90555
|
1963 |
|
|
VINCRISTINE SULFATE
CHEMBL501867
|
1963 |
|
|
FLUOROURACIL
CHEMBL185
|
1962 |
|
|
COLCHICINE
CHEMBL107
|
1961 |
|
|
DEXAMETHASONE
CHEMBL384467
|
1958 |
Source Header